Creyon is leading the development of a new class of cell-specific therapeutics using aptamer-delivered oligonucleotides. Our platform enables precise delivery to target cells—without the limitations of traditional antibody-based approaches. Our proprietary aptamers are engineered to deliver therapeutic payloads directly to T and B cells, opening new possibilities to modulate immune pathways and treat a wide range of immune-driven diseases.
Beyond oligonucleotides, our platform can also direct lipid nanoparticles (LNPs) to immune and other cell types.
Crossing the Blood Brain Barrier (BBB) with RNA Therapeutics
Our CNS program has established preclinical proof-of-concept demonstrating the ability to shuttle nucleic acid therapeutics across the BBB to reach disease-relevant targets in the brain. Importantly, this work validates an innovative delivery approach, positioning our transferrin receptor (TfR) aptamer to support a broad pipeline of CNS indications by efficiently delivering both small interfering RNA (siRNA) and antisense oligonucleotides (ASOs) into the CNS.
By harnessing our TfR aptamer for targeted delivery into muscle, we are advancing a first-in-class splice-switching oligonucleotide therapy for late-onset Pompe disease. This is the only approach that can restore endogenous acid alpha-glucosidase (GAA) production and sustain glycogen reduction.
Aptamer Delivery Technology
Creyon has built a highly precise targeting approach utilizing its novel aptamer delivery technology to potentially improve the benefit-risk advantage of therapies in our pipeline. Aptamers offer meaningful advantages over antibody-based delivery, including improved tissue penetration, more favorable pharmacology, reduced immunogenicity risks, and efficient CMC.
AI-Powered Nucleic Acid Engineering Platform
Coupled with our novel AI-Powered Nucleic Acid Engineering Platform (NuclelQ™), this approach enables a de-risked path to designing safe and active nucleic acid therapies by leveraging proprietary, purpose-built pharmacology datasets and AI/ML predictive tools.
Our Investors
